Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 41Carcinoma, Non-Small-Cell Lung 27Colorectal Neoplasms 17Neoplasms 13Prostatic Neoplasms 11Nasopharyngeal Carcinoma 11Lung Neoplasms 11Carcinoma, Hepatocellular 11Multiple Myeloma 9Leukemia, Myeloid, Acute 9Stomach Neoplasms 8Small Cell Lung Carcinoma 8Ovarian Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Rectal Neoplasms 7Esophageal Neoplasms 7Triple Negative Breast Neoplasms 6Pancreatic Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 6Neoplasm Metastasis 6Esophageal Squamous Cell Carcinoma 6Uterine Cervical Neoplasms 5Recurrence 5Glioblastoma 5Colonic Neoplasms 5Carcinoma, Renal Cell 5Brain Neoplasms 5Adenocarcinoma 5Urinary Bladder Neoplasms 4Lymphoma, Follicular 4

Interventions

trifluridine tipiracil drug combination 1tipiracil 1regorafenib 1Trifluridine 1Tablets 1HMPL-013 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × HER2 IHC3+ Advanced Colorectal Cancer × Clear all
NCT07483684 2026-03-19

A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Not yet recruiting
142 enrolled
Gastrointestinal

HER2 IHC3+ Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡